KYMR · earnings call history
Kymera Therapeutics Q2 FY26 — Accelerated KT-621 AD Enrollment and Pipeline Advancement
Read the briefKymera Therapeutics Q1 FY26 — Pipeline Advancement and Strong Financial Position
Read the briefKymera Therapeutics Q4 FY25 — Strong Pipeline Progress and Extended Cash Runway
Read the briefBrowse all US companies on the earnings-call register.